Breast Cancer Clinical Trials in Birmingham, Alabama

15 studies are recruiting for breast cancer in Birmingham, Alabama right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

    The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Alabama at Birmingham, Birmingham, Alabama
    Locations
    65 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT06618287 on ClinicalTrials.gov

  2. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Alabama Birmingham, Birmingham, Alabama
    Locations
    26 in total
    Run by
    SystImmune Inc.

    See if you can join NCT06293898 on ClinicalTrials.gov

  3. Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

    For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal residual disease (MRD), can lead to the cancer coming back later. A way to find these cells is by looking for tiny bits of cancer DNA that are …

    Stage
    Not phased
    Ages
    18 to 99
    Site
    Birmingham Hematology Associates, Birmingham, Alabama
    Locations
    16 in total
    Run by
    Tempus AI

    See if you can join NCT07211178 on ClinicalTrials.gov

  4. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with es…

    Stage
    Phase 3
    Ages
    18 to 60
    Site
    University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
    Locations
    1261 in total
    Run by
    NRG Oncology

    See if you can join NCT05879926 on ClinicalTrials.gov

  5. TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

    The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating HER2-negative (HE…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Alabama, Birmingham, Alabama
    Locations
    11 in total
    Run by
    Ana C Garrido-Castro, MD

    See if you can join NCT06533826 on ClinicalTrials.gov

  6. An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75202 (KAT6A/B inhibitor) alone and in combination with other therapies in participants with breast cancer and other advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Alabama At Birmingham Hospital, Birmingham, Alabama
    Locations
    31 in total
    Run by
    BeOne Medicines

    See if you can join NCT07222267 on ClinicalTrials.gov

  7. Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts

    The over-arching goal of the Contrast-Enhanced Spectral Mammography Imaging Screening Trial (CMIST) is to determine if dual-energy contrast-enhanced spectral mammography (CESM) can detect more cancers with fewer false positives than digital breast tomosynthesis (DBT) in women with dense breasts. Ai…

    Stage
    Not phased
    Ages
    45 to 74
    Site
    University of Alabama, Birmingham, Birmingham, Alabama
    Locations
    13 in total
    Run by
    American College of Radiology

    See if you can join NCT05625659 on ClinicalTrials.gov

  8. Promoting Resilience in Women With Breast Cancer (PRISM -MBC)

    This pilot interventional study evaluates the change from baseline to post-intervention in resilience and other patient-reported outcomes for individuals with a recent diagnosis of metastatic breast cancer (MBC) participating in the Promoting Resilience in Women with Breast Cancer (PRISM) intervent…

    Stage
    Not phased
    Ages
    18 and older
    Site
    The University of Alabama, Birmingham, Alabama
    Locations
    2 in total
    Run by
    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT06855654 on ClinicalTrials.gov

  9. I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic res…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Alabama at Birmingham, Birmingham, Alabama
    Locations
    42 in total
    Run by
    QuantumLeap Healthcare Collaborative

    See if you can join NCT01042379 on ClinicalTrials.gov

  10. Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness

    Our goal is to investigate the use of 89Zr-trastuzumab as a HER2 imaging agent to determine which patients are likely to respond to targeted HER2 agents as single agent therapy. We are proposing to perform a pilot study with goals of demonstrating the feasibility of imaging breast cancer patients w…

    Stage
    EARLY_Phase 1
    Ages
    18 and older
    Site
    The Kirklin Clinic, Birmingham, Alabama
    Run by
    University of Alabama at Birmingham

    See if you can join NCT03321045 on ClinicalTrials.gov

  11. Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators

    The purpose of this study is to test whether the timing of meals can improve treatment adverse events, influence tumor biology and alter a person's mood and behaviors.

    Stage
    Not phased
    Ages
    18 and older
    Site
    The University of Alabama at Birmingham, Birmingham, Alabama
    Locations
    2 in total
    Run by
    Cedars-Sinai Medical Center

    See if you can join NCT04722341 on ClinicalTrials.gov

  12. Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

    Most physicians still use a one-size-fits-all approach to breast screening in which all women, regardless of their personal history, family history or genetics (except BRCA carriers) are recommended to have annual mammograms starting at age 40. Mammograms benefit women by detecting cancers early wh…

    Stage
    Not phased
    Ages
    30 to 74
    Site
    University of Alabama at Birmingham, Birmingham, Alabama
    Locations
    11 in total
    Run by
    University of California, San Francisco

    See if you can join NCT02620852 on ClinicalTrials.gov

  13. RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)

    This study offers 5 fractions of radiation treatment through partial breast irradiation in patients with early stage breast cancer after having a lumpectomy.

    Stage
    Not phased
    Ages
    18 to 99
    Site
    University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center (HSROC), Birmingham, Alabama
    Run by
    University of Alabama at Birmingham

    See if you can join NCT03643861 on ClinicalTrials.gov

  14. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Birmingham, Alabama
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

  15. MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

    The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enabl…

    Stage
    Not phased
    Ages
    18 and older
    Site
    CHS Grandview, Birmingham, Alabama
    Locations
    134 in total
    Run by
    Agendia

    See if you can join NCT03053193 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.